Detalhe da pesquisa
1.
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.
BMC Med Res Methodol
; 22(1): 155, 2022 05 30.
Artigo
Inglês
| MEDLINE | ID: mdl-35637426
2.
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.
J Med Econ
; 27(1): 109-125, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38085684
3.
Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study.
Mult Scler Relat Disord
; 58: 103404, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-35216786